Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences ...
With healthcare costs dominating the conversation in recent years, the topic of employer-covered healthcare is a key issue.
Jun Gong, MD, associate professor of medicine and medical director of colorectal cancer at Cedars-Sinai, spoke with ...
FDA cleared belzutifan 120 mg plus lenvatinib 20 mg daily for advanced RCC with a clear cell component after prior PD-1/PD-L1 inhibitor exposure. LITESPARK-011 randomized 747 patients to ...
Novo Nordisk secured Pharmashell access for up to five peptide programs, targeting long-acting injectable profiles and offering Nanexa >$1.33B total consideration plus low single-digit royalties.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results